However, in the setting of KRAS-mutant CRC, the ORR was only 8%, which indicated the limited antitumor activity of trastuzumab plus pertuzumab (Meric-Bernstam et al., 2019). This evidence concerns the gene KRAS and colorectal carcinoma.